MedTrace Logo

The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease

NCT05020106 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3200

Last updated 2026-03-23

No results posted yet for this study

Summary

The participant in this study includes Alzheimer's disease (AD including familial AD and sporadic AD) patients, amnestic mild cognitive impairment (aMCI) patients, non-AD dementia patients and cognitively normal control.

The purpose of this study is to establish the best cut-off value of cerebrospinal fluid (CSF) and blood β-amyloid (Aβ) 42/40, total tau (t-tau) , phosphorylated tau ,inflammatory factors, etc. in diagnosis of Alzheimer's disease (AD).

Conditions

Sponsors & Collaborators

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • The First Hospital of Jilin University

    collaborator OTHER

  • Capital Medical University

    lead OTHER

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2027-09-01
Completion
2027-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05020106 on ClinicalTrials.gov